Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PREMARIN® INTRAVENOUS Adverse Reactions (conjugated estrogens)

ADVERSE REACTIONS

See BOXED WARNINGS, WARNINGS, and PRECAUTIONS.

Premarin Intravenous for injection is indicated for short-term use. However, the warnings, precautions and adverse reactions associated with oral Premarin treatment should be taken into account.

The following adverse reactions have been identified during post-approval use of oral or intravenous Premarin. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Genitourinary system

 
Abnormal uterine bleeding/spotting.
 
Dysmenorrhea or pelvic pain.
 
Increase in size of uterine leiomyomata.
 
Vaginitis, including vaginal candidiasis.
 
Change in amount of cervical secretion.
 
Change in cervical ectropion.
 
Ovarian cancer.
 
Endometrial hyperplasia.
 
Endometrial cancer.

Breasts

 
Tenderness, enlargement, pain, discharge, galactorrhea.
 
Fibrocystic breast changes.
 
Breast cancer.

Cardiovascular

 
Deep and superficial venous thrombosis.
 
Pulmonary embolism.
 
Thrombophlebitis.
 
Myocardial infarction.
 
Stroke.
 
Increase in blood pressure.

Gastrointestinal

 
Nausea, vomiting.
 
Abdominal cramps, bloating.
 
Cholestatic jaundice.
 
Increased incidence of gallbladder disease.
 
Pancreatitis.
 
Enlargement of hepatic hemangiomas.
 
Ischemic colitis.

Skin

 
Chloasma or melasma that may persist when drug is discontinued.
 
Erythema multiforme.
 
Erythema nodosum.
 
Hemorrhagic eruption.
 
Loss of scalp hair.
 
Hirsutism.
 
Pruritis.
 
Rash.

Eyes

 
Retinal vascular thrombosis.
 
Intolerance to contact lenses.

Central Nervous System

 
Headache.
 
Migraine.
 
Dizziness.
 
Mental depression.
 
Exacerbation of chorea.
 
Nervousness.
 
Exacerbation of epilepsy.
 
Dementia.
 
Possible growth potentiation of benign meningioma.

Miscellaneous

 
Increase or decrease in weight.
 
Glucose intolerance.
 
Aggravation of porphyria.
 
Edema.
 
Arthralgia.
 
Leg cramps.
 
Changes in libido.
 
Urticaria.
 
Hypocalcemia (preexisting condition).
 
Injection site pain.
 
Injection site edema.
 
Phlebitis (injection site).
 
Exacerbation of asthma.
 
Increased triglycerides.
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event